Calendar Companies Compare Analytics Learn Watchlist

Search CatalystAlert

Search for companies, drugs, and catalysts

Loading market movers...

Free biotech catalyst calendar tracking FDA decisions, clinical trial results, and PDUFA dates for biotech stocks.

Quick Links

Catalyst Calendar
Search Companies
Biotech Glossary
Therapeutic Areas

Legal

About
Privacy
Terms

Data Sources

ClinicalTrials.gov
SEC EDGAR
FDA

© 2025 CatalystAlert. All rights reserved.

Not financial advice. Data may be delayed or incomplete.

Ziltivekimab B - Phase 3 | NOVO-B.CO Pipeline | CatalystAlert

Back to NOVO-B.CO

Ziltivekimab B

Phase 3

Novo Nordisk A/S (NOVO-B.CO)

55%

Phase 3

Development Phase

1

Upcoming Catalysts

0

Historical Events

0

Regulatory Approvals

Upcoming Catalysts

Jun 26

NOVO-B.CO⭐Phase 3Phase 3

Ziltivekimab B Phase 3 Results Expected

Ziltivekimab B • Cardiovascular Risk

Drug Information

Target Indication

Cardiovascular Risk

Clinical Trial

Last updated: 12/4/2025

Developer

NOVO-B.CO

Novo Nordisk A/S

Biotechnology•North America•NASDAQ